Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

NCT: NCT06374264 · ENROLLING_BY_INVITATION

NCT IDNCT06374264
StatusENROLLING_BY_INVITATION
Start Date2024-11-12
Completion2026-12-31
SponsorMedRhythms, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.

Frequently Asked Questions

What is Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder?

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder is a clinical trial registered under NCT06374264. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT06374264?

The current status of NCT06374264 (Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder) is: ENROLLING_BY_INVITATION.

When did Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder start?

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder started on 2024-11-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑